NeuroVive’s Clinical Development Project KL1333 Receives Positive Opinion on European Orphan Drug Designation
Lund, Sweden, 8 November 2017 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has provided a positive opinion on granting Orphan Drug Designation in the European Union for NeuroVive’s KL1333 for oral treatment of the genetic mitochondrial disease Mitochondrial Myopathy, Encephalopathy, Lactic acidosis and Stroke-like episodes (MELAS).The European Commission will issue its formal decision based on the opinion approximately one